Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
136.5 GBX | 0.00% | +6.23% | -25.21% |
04-23 | Arecor chief financial officer to leave in July after five years | AN |
04-23 | Arecor Therapeutics CFO to Leave in July | MT |
Sales 2023 * | 5.01M 6.26M 501M | Sales 2024 * | 7.58M 9.47M 758M | Capitalization | 41.81M 52.22M 4.18B |
---|---|---|---|---|---|
Net income 2023 * | -6M -7.5M -600M | Net income 2024 * | -6M -7.5M -600M | EV / Sales 2023 * | 7.11 x |
Net cash position 2023 * | 6.17M 7.71M 617M | Net cash position 2024 * | 2.08M 2.6M 208M | EV / Sales 2024 * | 5.24 x |
P/E ratio 2023 * |
-5.69
x | P/E ratio 2024 * |
-6.35
x | Employees | 51 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 48.52% |
Latest transcript on Arecor Therapeutics plc
1 week | +6.23% | ||
Current month | -2.50% | ||
1 month | -4.55% | ||
3 months | -17.77% | ||
6 months | -28.16% | ||
Current year | -25.21% |
Managers | Title | Age | Since |
---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 49 | - |
Susan Lowther
DFI | Director of Finance/CFO | 65 | 31/12/18 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Smith
BRD | Director/Board Member | 78 | - |
Christine Soden
BRD | Director/Board Member | 66 | 30/04/21 |
Andrew Richards
CHM | Chairman | 64 | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 136.5 | 0.00% | 19,481 |
25/04/24 | 136.5 | 0.00% | 28,346 |
24/04/24 | 136.5 | +3.02% | 22,700 |
23/04/24 | 132.5 | 0.00% | 10,876 |
22/04/24 | 132.5 | +3.11% | 18,774 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.21% | 52.07M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AREC Stock